209 related articles for article (PubMed ID: 22150825)
1. Improving the flexibility and efficiency of phase II designs for oncology trials.
Englert S; Kieser M
Biometrics; 2012 Sep; 68(3):886-92. PubMed ID: 22150825
[TBL] [Abstract][Full Text] [Related]
2. Adaptive designs for single-arm phase II trials in oncology.
Englert S; Kieser M
Pharm Stat; 2012; 11(3):241-9. PubMed ID: 22411839
[TBL] [Abstract][Full Text] [Related]
3. Estimation of secondary endpoints in two-stage phase II oncology trials.
Kunz CU; Kieser M
Stat Med; 2012 Dec; 31(30):4352-68. PubMed ID: 22930470
[TBL] [Abstract][Full Text] [Related]
4. Methods for proper handling of overrunning and underrunning in phase II designs for oncology trials.
Englert S; Kieser M
Stat Med; 2015 Jun; 34(13):2128-37. PubMed ID: 25781860
[TBL] [Abstract][Full Text] [Related]
5. Designs for phase II trials allowing for a trade-off between response and toxicity.
Conaway MR; Petroni GR
Biometrics; 1996 Dec; 52(4):1375-86. PubMed ID: 8962459
[TBL] [Abstract][Full Text] [Related]
6. Performance of adaptive designs for single-armed phase II oncology trials.
Kieser M; Englert S
J Biopharm Stat; 2015; 25(3):602-15. PubMed ID: 24905363
[TBL] [Abstract][Full Text] [Related]
7. Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.
Masaki N; Koyama T; Yoshimura I; Hamada C
J Biopharm Stat; 2009 Jul; 19(4):721-31. PubMed ID: 20183436
[TBL] [Abstract][Full Text] [Related]
8. Optimal adaptive two-stage designs for phase II cancer clinical trials.
Englert S; Kieser M
Biom J; 2013 Nov; 55(6):955-68. PubMed ID: 23868324
[TBL] [Abstract][Full Text] [Related]
9. Continuous toxicity monitoring in phase II trials in oncology.
Ivanova A; Qaqish BF; Schell MJ
Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
[TBL] [Abstract][Full Text] [Related]
10. A new adaptive design based on Simon's two-stage optimal design for phase II clinical trials.
Jin H; Wei Z
Contemp Clin Trials; 2012 Nov; 33(6):1255-60. PubMed ID: 22772088
[TBL] [Abstract][Full Text] [Related]
11. Curtailment in single-arm two-stage phase II oncology trials.
Kunz CU; Kieser M
Biom J; 2012 Jul; 54(4):445-56. PubMed ID: 22610516
[TBL] [Abstract][Full Text] [Related]
12. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
[TBL] [Abstract][Full Text] [Related]
13. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
14. A comparison of methods for adaptive treatment selection.
Friede T; Stallard N
Biom J; 2008 Oct; 50(5):767-81. PubMed ID: 18932136
[TBL] [Abstract][Full Text] [Related]
15. An efficient algorithm to determine the optimal two-stage randomized multinomial designs in oncology clinical trials.
Zhang Y; Mietlowski W; Chen B; Wang Y
J Biopharm Stat; 2011 Jan; 21(1):56-65. PubMed ID: 21191854
[TBL] [Abstract][Full Text] [Related]
16. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
Jenkins M; Stone A; Jennison C
Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
[TBL] [Abstract][Full Text] [Related]
17. A flexible multi-stage design for phase II oncology trials.
Tan MT; Xiong X
Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
[TBL] [Abstract][Full Text] [Related]
18. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
Shan G; Ma C; Hutson AD; Wilding GE
J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
[TBL] [Abstract][Full Text] [Related]
19. Targeting population entering phase III trials: a new stratified adaptive phase II design.
Tournoux-Facon C; De Rycke Y; Tubert-Bitter P
Stat Med; 2011 Apr; 30(8):801-11. PubMed ID: 21432875
[TBL] [Abstract][Full Text] [Related]
20. Curtailed two-stage designs in Phase II clinical trials.
Chi Y; Chen CM
Stat Med; 2008 Dec; 27(29):6175-89. PubMed ID: 18816510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
